A phase III comparative study to evaluate the efficacy and safety of SJP-0125 versus brimonidine tartrate in patients with primary open-angle glaucoma or ocular hypertension - A comparative study to evaluate the efficacy and safety of SJP-0125 versus brimonidine tartrate in patients with primary open-angle glaucoma or ocular hypertension

Senju Pharmaceutical Co.,Ltd.0 个研究点目标入组 320 人开始时间: 2017年9月16日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Prior ocular instillation of SJP-0125 2) History of surgical intervention or laser treatment for glaucoma 3) History of intraocular surgery within past 90 days 4) Anticipated wearing of any contact lenses 5) Intraocular injection, sub-Tenon or subconjunctival injection of a corticosteroid agent within past 180 days 6) Patients who are pregnant, breastfeeding, or potentially pregnant. or who desire to be pregnant or who do not intend to prevent conception from consent to the end of the treatment period 7) Participated in any other clinical trial within past 90 days and received any other investigational drug or plans to participate in any other clinical trial during the study 8) Presence of any active retinal disease which may progress during the study 9) Presence of any active ocular disease other than primary open-angle glaucoma (broad definition) or ocular hypertension 10) Presence of a cancer or a serious systemic disease 11) Presence of any circulatory failure 12) Presence of corneal disorder 13) Presence of serious visual field defect 14) Presence of corneal abnormality which is considered to preclude accurate measurement of IOP by Goldmann applanation tonometer 15) History of corneal transplantation or keratorefractive surgery 16) History of allergy or significant adverse drug reaction to any ingredients of drugs used in this study

发起方